ImmunoPrecise Antibodies’ (IPA) “Buy” Rating Reiterated at HC Wainwright

HC Wainwright reiterated their buy rating on shares of ImmunoPrecise Antibodies (NASDAQ:IPA) in a research note released on Tuesday, Benzinga reports. HC Wainwright currently has a $9.00 price target on the stock. HC Wainwright also issued estimates for ImmunoPrecise Antibodies’ Q1 2025 earnings at ($0.09) EPS, Q4 2025 earnings at ($0.05) EPS, FY2025 earnings at ($0.25) EPS, FY2026 earnings at ($0.14) EPS, FY2027 earnings at $0.02 EPS, FY2028 earnings at $0.20 EPS and FY2029 earnings at $0.42 EPS.

ImmunoPrecise Antibodies Trading Down 2.5 %

ImmunoPrecise Antibodies stock opened at $0.84 on Tuesday. The stock has a 50-day moving average of $0.98 and a two-hundred day moving average of $1.35. The company has a debt-to-equity ratio of 0.36, a quick ratio of 1.38 and a current ratio of 1.41. ImmunoPrecise Antibodies has a one year low of $0.77 and a one year high of $2.60. The stock has a market cap of $22.68 million, a PE ratio of -2.05 and a beta of 0.10.

Institutional Inflows and Outflows

An institutional investor recently raised its position in ImmunoPrecise Antibodies stock. Ingalls & Snyder LLC lifted its position in ImmunoPrecise Antibodies Ltd. (NASDAQ:IPA) by 24.6% in the 4th quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund owned 1,281,305 shares of the company’s stock after purchasing an additional 253,052 shares during the quarter. Ingalls & Snyder LLC owned about 4.87% of ImmunoPrecise Antibodies worth $2,191,000 as of its most recent SEC filing. Institutional investors own 6.70% of the company’s stock.

ImmunoPrecise Antibodies Company Profile

ImmunoPrecise Antibodies Ltd., together with its subsidiaries, operates as a biotherapeutic research and technology company in Canada and internationally. It provides NonaVac DNA for complex protein classes, including GPCRs and ion channels; and Rapid Prime, a positive monoclonal antibodies for generating anti-idiotypic antibodies, and producing monoclonal antibodies against conformational epitopes.